Coherus Oncology (CHRS) Payables (2013 - 2026)

Coherus Oncology has disclosed Payables across 14 years of filings, most recently posting $13.2 million for Q2 2026.

• In Q2 2026, Payables fell 65.0% year-over-year to $13.2 million; the TTM figure through Jun 2026 stood at $13.2 million (down 65.0% YoY), while the FY2025 annual figure was $9.9 million, down 76.44% from the prior year.
• Payables came in at $13.2 million for Q2 2026 at Coherus Oncology, up from $11.5 million in the prior quarter.
• In the past five years, Payables ranged from a high of $86.0 million in Q2 2024 to a low of $9.9 million in Q4 2025.
• Average Payables over 5 years is $30.4 million, with a median of $27.1 million recorded in 2023.
• Year-over-year, Payables slumped 92.17% in 2022 and soared 274.02% in 2023.
• Over 5 years, Payables stood at $11.5 million in 2022, then jumped by 205.56% to $35.2 million in 2023, then advanced by 19.47% to $42.1 million in 2024, then tumbled by 76.44% to $9.9 million in 2025, then soared by 32.81% to $13.2 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $13.2 million in Q2 2026, $11.5 million in Q1 2026, and $9.9 million in Q4 2025.